drugset
drugset / Trial / NCT04344236

Gargling and Nasal Rinses to Reduce Oro- and Nasopharyngeal Viral Load in Patients With COVID-19

NCT04344236 ↗

Phase 2 Withdrawn NYU Langone Health
RandomizedParallel-groupOpen-labelTreatment

Summary

For this study, 48 patients who have been diagnosed with COVID-19 will be randomly assigned to four study groups: control, saline, chlorhexidine gluconate, and povidone-iodine. Each patient will be asked to gargle with a solution of either saline, chlorhexidine gluconate, or povidone-iodine or nothing (control group) as well as spray the same solution in their nose four times daily. Patients will then be tested for COVID-19 once daily in the evening for 7 days and viral loads will be measured.

Timeline

Start
2020-04-09
Primary completion
2020-05-01
Completion
2020-05-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Chlorhexidine Small molecule 0.12 % Intranasal
Subject Chlorhexidine Small molecule 5 ml Intranasal
Subject Chlorhexidine Small molecule 20 ml Intranasal
Subject Iodine Unknown 0.5 % Intranasal
Subject Iodine Unknown 5 ml Intranasal
Subject Iodine Unknown 20 ml Intranasal
Subject sodium chloride Unknown 5 ml Intranasal
Subject sodium chloride Unknown 20 ml Intranasal

Indications

COVID-19